Cell surface anchoring antigen conjugates to treat cancer
OwnerTianxin Wanginventor
Life of this patent
Estimating the term…
Abstract
This disclosure provides cell surface anchoring antigen conjugates, formulations comprising cell surface anchoring antigen conjugates, and methods of using the same for treating cancer.
Claims6
A pharmaceutical composition comprising a cell surface anchoring antigen conjugate and a Toll-like receptors (TLR) agonist selected from a group consisting of poly IC, imiquimod or a mixture thereof, wherein the cell surface anchoring antigen conjugate contains a 3β-cholesterylamine moiety and a galactose-alpha-1,3-galactose (α-gal) moiety as antigen of pre-existing endogenous anti α-gal antibody, having a formula:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a cell surface anchoring antigen conjugate and a Toll-like receptors (TLR) agonist selected from a group consisting of poly IC, imiquimod or a mixture thereof, wherein the cell surface anchoring antigen conjugate is a conjugate of L-rhamnose with 3β-cholesterylamine having formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.